{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:28:17Z","timestamp":1787041697154,"version":"build-2736575974"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119150","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:13:06Z","timestamp":1783699986000},"page":"119150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting P2X receptors for analgesia: Small molecule antagonists in development"],"prefix":"10.1016","volume":"317","author":[{"given":"Zhibin","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenning","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1997-3595","authenticated-orcid":false,"given":"Jiaying","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119150_bib1","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","article-title":"The revised international association for the study of pain definition of pain: concepts, challenges, and compromises","volume":"161","author":"Raja","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2026.119150_bib2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1186\/1471-2458-11-770","article-title":"Pain as a global public health priority","volume":"11","author":"Goldberg","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ejmech.2026.119150_bib3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.hoc.2022.06.009","article-title":"Chronic pain: prevalence and management","volume":"36","author":"Carroll","year":"2022","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2026.119150_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mayocp.2012.08.020","article-title":"Why patients visit their doctors: assessing the most prevalent conditions in a defined American population","volume":"88","author":"St Sauver","year":"2013","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejmech.2026.119150_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41392-024-01845-w","article-title":"Pathology of pain and its implications for therapeutic interventions","volume":"9","author":"Cao","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119150_bib6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.mayocp.2015.04.010","article-title":"Opioid analgesics","volume":"90","author":"Jamison","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejmech.2026.119150_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinme.2025.100330","article-title":"Opioid analgesics: managing the predictable","volume":"25","author":"Barnes","year":"2025","journal-title":"Clin. Med."},{"key":"10.1016\/j.ejmech.2026.119150_bib8","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMra025411","article-title":"Opioid therapy for chronic pain","volume":"349","author":"Ballantyne","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119150_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0140-6736(16)31267-3","article-title":"Opioid analgesics","volume":"388","author":"Allende-P\u00e9rez","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119150_bib10","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/add.16616","article-title":"Prevalence of problematic pharmaceutical opioid use in patients with chronic non-cancer pain: a systematic review and meta-analysis","volume":"119","author":"Thomas","year":"2024","journal-title":"Addiction"},{"key":"10.1016\/j.ejmech.2026.119150_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-086001","article-title":"Traditional laxatives in preventing opioid-induced constipation in adult patients with cancer: a systematic review and meta-analysis protocol","volume":"14","author":"Long","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejmech.2026.119150_bib12","article-title":"Postoperative opioid-induced respiratory depression: who are at the greatest risk?","volume":"46","author":"Mohammad Goudarzi-Rad","year":"2024","journal-title":"CMBES Proc"},{"key":"10.1016\/j.ejmech.2026.119150_bib13","first-page":"43","article-title":"Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population, pharmacoepidemiol","volume":"23","author":"Zhou","year":"2014","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2026.119150_bib14","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(99)00362-9","article-title":"Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications","volume":"107","author":"Bjorkman","year":"1999","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejmech.2026.119150_bib15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0022-3565(24)38195-9","article-title":"Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids","volume":"289","author":"Catella-Lawson","year":"1999","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119150_bib16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.96.1.272","article-title":"Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2","volume":"96","author":"McAdam","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.119150_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2026.119150_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.925880","article-title":"Molecular pharmacology of P2X receptors: exploring druggable domains revealed by structural biology","volume":"13","author":"Oken","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107072","article-title":"Use of automated patch clamp in cardiac safety assessment: past, present and future perspectives","volume":"110","author":"Bell","year":"2021","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejmech.2026.119150_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17460441.2020.1791079","article-title":"Automated patch clamp in drug discovery: major breakthroughs and innovation in the last decade","volume":"16","author":"Obergrussberger","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119150_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.858348","article-title":"Druggability of voltage-gated sodium channels-exploring old and new drug receptor sites","volume":"13","author":"Wisedchaisri","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1124\/mol.107.038901","article-title":"The unusual state-dependent affinity of P2X3 receptors can be explained by an allosteric two-open-state model","volume":"73","author":"Karoly","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1039\/D5CC05022G","article-title":"Nanobodies targeting ion channels: advancing therapeutics through precision and structural insights","volume":"62","author":"Baral","year":"2026","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.119150_bib24","doi-asserted-by":"crossref","first-page":"8283","DOI":"10.1038\/s41467-025-62643-8","article-title":"A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor","volume":"16","author":"Oken","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119150_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bph.15299","article-title":"Update of P2X receptor properties and their pharmacology: IUPHAR review 30","volume":"178","author":"Illes","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11302-022-09850-w","article-title":"Enlightening activation gating in P2X receptors","volume":"18","author":"Sattler","year":"2022","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2026.119150_bib27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11302-020-09743-w","article-title":"Nociceptive signaling of P2X receptors in chronic pain states","volume":"17","author":"Inoue","year":"2021","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2026.119150_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177052","article-title":"P2X3 and P2X2\/3 receptors inhibition produces a consistent analgesic efficacy: a systematic review and meta-analysis of preclinical studies","volume":"984","author":"Huerta","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105106","article-title":"The role and pharmacological characteristics of ATP-gated ionotropic receptor P2X in cancer pain","volume":"161","author":"Zhang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119150_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115234","article-title":"From lead to clinic: a review of the structural design of P2X7R antagonists","volume":"251","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib31","article-title":"Involvement of microglial P2X7 receptor in pain modulation","volume":"30","author":"Zhang","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejmech.2026.119150_bib32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/WNR.0000000000001266","article-title":"P2X receptors and trigeminal neuralgia","volume":"30","author":"Li","year":"2019","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejmech.2026.119150_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13041-016-0240-4","article-title":"Nociceptive transmission and modulation via P2X receptors in central pain syndrome","volume":"9","author":"Kuan","year":"2016","journal-title":"Mol. Brain"},{"key":"10.1016\/j.ejmech.2026.119150_bib34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0304-3959(77)90066-5","article-title":"Observations on the algogenic actions of adenosine compounds on the human blister base preparation","volume":"3","author":"Bleehen","year":"1977","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2026.119150_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2015.12.001","article-title":"Medicinal chemistry of adenosine, P2Y and P2X receptors","volume":"104","author":"Jacobson","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2026.119150_bib36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0163-7258(94)00048-4","article-title":"Purinoceptors: are there families of P2X and P2Y purinoceptors?","volume":"64","author":"Abbracchio","year":"1994","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119150_bib37","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11302-021-09813-7","article-title":"Recommended tool compounds and drugs for blocking P2X and P2Y receptors","volume":"17","author":"M\u00fcller","year":"2021","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2026.119150_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/371519a0","article-title":"New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor","volume":"371","author":"Brake","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib39","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/371516a0","article-title":"A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP","volume":"371","author":"Valera","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib40","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/377428a0","article-title":"A P2X purinoceptor expressed by a subset of sensory neurons","volume":"377","author":"Chen","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib41","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/S0140-6736(96)91082-X","article-title":"A unifying purinergic hypothesis for the initiation of pain","volume":"347","author":"Burnstock","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119150_bib42","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nature01786","article-title":"P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury","volume":"424","author":"Tsuda","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib43","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nature08198","article-title":"Crystal structure of the ATP-gated P2X4 ion channel in the closed state","volume":"460","author":"Kawate","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature11010","article-title":"Molecular mechanism of ATP binding and ion channel activation in P2X receptors","volume":"485","author":"Hattori","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib45","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.22153","article-title":"Structural basis for subtype-specific inhibition of the P2X7 receptor","volume":"5","author":"Karasawa","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.119150_bib46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature19367","article-title":"X-ray structures define human P2X3 receptor gating cycle and antagonist action","volume":"538","author":"Mansoor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib47","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cell.2019.09.017","article-title":"Full-length P2X7 structures reveal how palmitoylation prevents channel desensitization","volume":"179","author":"McCarthy","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119150_bib48","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2174\/0929867322666141210155610","article-title":"Medicinal chemistry of P2X receptors: allosteric modulators","volume":"22","author":"M\u00fcller","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib49","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1073\/pnas.1800907115","article-title":"Druggable negative allosteric site of P2X3 receptors","volume":"115","author":"Wang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.119150_bib50","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1038\/s41467-023-42164-y","article-title":"Structural insights into the allosteric inhibition of P2X4 receptors","volume":"14","author":"Shen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119150_bib51","doi-asserted-by":"crossref","first-page":"eadr3315","DOI":"10.1126\/sciadv.adr3315","article-title":"Human P2X4 receptor gating is modulated by a stable cytoplasmic cap and a unique allosteric pocket","volume":"11","author":"Shi","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.119150_bib52","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev.pharmtox.40.1.563","article-title":"Pharmacology of cloned P2X receptors","volume":"40","author":"North","year":"2000","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119150_bib53","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neuropharm.2008.06.067","article-title":"ATP-gated P2X cation-channels","volume":"56","author":"Jarvis","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2026.119150_bib54","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gky473","article-title":"CASTp 3.0: computed atlas of surface topography of proteins","volume":"46","author":"Tian","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119150_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.108109","article-title":"Mechanistic insights into the selective targeting of P2X3 receptor by camlipixant antagonist","volume":"301","author":"Thach","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fncel.2019.00121","article-title":"An allosteric inhibitory site conserved in the ectodomain of P2X receptor channels","volume":"13","author":"Ase","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119150_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105454","article-title":"Molecular dynamic simulations of full-length human purinergic receptor subtype P2X7 bonded to potent inhibitors","volume":"152","author":"Dos Santos","year":"2020","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2026.119150_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1101023","article-title":"Identification of the molecular determinants of antagonist potency in the allosteric binding pocket of human P2X4","volume":"14","author":"Pasqualetto","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2024.108285","article-title":"In-silico screening to identify phytochemical inhibitor for hP2X7: a crucial inflammatory cell death mediator in Parkinson's disease","volume":"115","author":"Khan","year":"2025","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114556","article-title":"AI-based prediction of new binding site and virtual screening for the discovery of novel P2X3 receptor antagonists","volume":"240","author":"Kang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66244-3","article-title":"Discovery of an allosteric binding site for anthraquinones at the human P2X4 receptor","volume":"16","author":"Nagel","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119150_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1685425","article-title":"Modeling the P2X7 receptor: a comparative analysis of conventional methods and AlphaFold","volume":"17","author":"Lima","year":"2026","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib63","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11302-023-09978-3","article-title":"Deep learning structural insights into heterotrimeric alternatively spliced P2X7 receptors","volume":"20","author":"De Salis","year":"2024","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2026.119150_bib64","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/377432a0","article-title":"Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons","volume":"377","author":"Lewis","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib65","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/387505a0","article-title":"Distinct ATP receptors on pain-sensing and stretch-sensing neurons","volume":"387","author":"Cook","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib66","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1124\/mol.58.5.936","article-title":"Characterization of calcium signaling by purinergic receptor-channels expressed in excitable cells","volume":"58","author":"Koshimizu","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib67","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/35039519","article-title":"Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice","volume":"407","author":"Cockayne","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib68","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/35039526","article-title":"Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors","volume":"407","author":"Souslova","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib69","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/sj.bjp.0705574","article-title":"Effects of A-317491, a novel and selective P2X3\/P2X2\/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration","volume":"140","author":"McGaraughty","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib70","doi-asserted-by":"crossref","first-page":"17179","DOI":"10.1073\/pnas.252537299","article-title":"A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2\/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat","volume":"99","author":"Jarvis","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2026.119150_bib71","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/nature04223","article-title":"BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain","volume":"438","author":"Coull","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119150_bib72","doi-asserted-by":"crossref","first-page":"11263","DOI":"10.1523\/JNEUROSCI.2308-08.2008","article-title":"Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain","volume":"28","author":"Ulmann","year":"2008","journal-title":"J. Neurosci."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2026.119150_bib73","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/j.pain.0000000000000389","article-title":"Sex differences in pain: a tale of two immune cells","volume":"157","author":"Mapplebeck","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2026.119150_bib74","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nn.4053","article-title":"Different immune cells mediate mechanical pain hypersensitivity in male and female mice","volume":"18","author":"Sorge","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119150_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/srep32461","article-title":"A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain","volume":"6","author":"Matsumura","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119150_bib76","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neulet.2011.08.058","article-title":"Induction of the P2X7 receptor in spinal microglia in a neuropathic pain model","volume":"504","author":"Kobayashi","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2026.119150_bib77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2X7 receptor in infection and inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2026.119150_bib78","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.4049\/jimmunol.176.7.3877","article-title":"The P2X7 receptor: a key player in IL-1 processing and release","volume":"176","author":"Ferrari","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2026.119150_bib79","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbr.2005.09.024","article-title":"Interleukin-1alphabeta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain","volume":"167","author":"Honore","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2026.119150_bib80","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pain.2005.01.002","article-title":"Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain","volume":"114","author":"Chessell","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2026.119150_bib81","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1124\/jpet.106.111559","article-title":"A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat","volume":"319","author":"Honore","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119150_bib82","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.apha.2015.09.001","article-title":"Purinergic mechanisms and pain","volume":"75","author":"Burnstock","year":"2016","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114309","article-title":"Nociceptive signaling mediated by P2X3, P2X4 and P2X7 receptors","volume":"187","author":"Inoue","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib84","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/sj.bjp.0702960","article-title":"Evidence for the involvement of spinal endogenous ATP and P2X receptors in nociceptive responses caused by formalin and capsaicin in mice","volume":"128","author":"Tsuda","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib85","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0304-3959(01)00434-1","article-title":"TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics","volume":"96","author":"Honore","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2026.119150_bib86","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/sj.bjp.0702001","article-title":"2',3'-O-(2,4,6- trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP)-a nanomolar affinity antagonist at rat mesenteric artery P2X receptor ion channels","volume":"124","author":"Lewis","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2012.05.008","article-title":"Chronic administration of the selective P2X3, P2X2\/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice","volume":"688","author":"Hansen","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib88","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.sjpain.2016.09.011","article-title":"Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain","volume":"14","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2017","journal-title":"Scand J Pain"},{"key":"10.1016\/j.ejmech.2026.119150_bib89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejphar.2004.09.056","article-title":"A-317491, a selective P2X3\/P2X2\/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats","volume":"504","author":"Wu","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib90","series-title":"Diaminopyrimidines as P2X3 and P2X2\/3 Antagonists","author":"Carter D","year":"2005"},{"key":"10.1016\/j.ejmech.2026.119150_bib91","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bmcl.2009.02.003","article-title":"Identification and SAR of novel diaminopyrimidines. Part 1: the discovery of RO-4, a dual P2X3\/P2X2\/3 antagonist for the treatment of pain","volume":"19","author":"Carter","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib92","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11302-010-9182-y","article-title":"Emerging structures and ligands for P2X3 and P2X4 receptors-towards novel treatments of neuropathic pain","volume":"6","author":"M\u00fcller","year":"2010","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2026.119150_bib93","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1093\/brain\/awq194","article-title":"Systemic blockade of P2X3 and P2X2\/3 receptors attenuates bone cancer pain behaviour in rats","volume":"133","author":"Kaan","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.ejmech.2026.119150_bib94","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1213\/ANE.0000000000001883","article-title":"Isobolographic analysis of drug combinations with intrathecal BRL52537 (\u03ba-opioid agonist), pregabalin (calcium channel modulator), AF 353 (P2X3 receptor antagonist), and A804598 (P2X7 receptor antagonist) in neuropathic rats","volume":"125","author":"Jung","year":"2017","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.ejmech.2026.119150_bib95","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.bmcl.2009.01.097","article-title":"Identification and SAR of novel diaminopyrimidines. Part 2: the discovery of RO-51, a potent and selective, dual P2X3\/P2X2\/3 antagonist for the treatment of pain","volume":"19","author":"Jahangir","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib96","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/tx200211v","article-title":"Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety","volume":"24","author":"Meanwell","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119150_bib97","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/bph.14677","article-title":"Action of MK-7264 (gefapixant) at human P2X3 and P2X2\/3 receptors and in vivo efficacy in models of sensitisation","volume":"176","author":"Richards","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib98","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fncel.2013.00267","article-title":"The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders","volume":"7","author":"Ford","year":"2013","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119150_bib99","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.fertnstert.2024.09.013","article-title":"Randomized, controlled, proof-of-concept trial of gefapixant for endometriosis-related pain","volume":"123","author":"Arbelaez","year":"2025","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.ejmech.2026.119150_bib100","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1476-5381.2011.01322.x","article-title":"Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2\/3 receptors with in vivo efficacy in a pain model","volume":"163","author":"Ballini","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejmech.2013.04.037","article-title":"Evaluation of adenine as scaffold for the development of novel P2X3 receptor antagonists","volume":"65","author":"Lambertucci","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib102","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.csbj.2022.03.030","article-title":"P2X3-selective mechanism of gefapixant, a drug candidate for the treatment of refractory chronic cough","volume":"20","author":"Cui","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejmech.2026.119150_bib103","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bmcl.2018.02.039","article-title":"Identification of second-generation P2X3 antagonists for treatment of pain","volume":"28","author":"Ginnetti","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib104","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99177-0","article-title":"Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers","volume":"11","author":"Davenport","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119150_bib105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/j.pain.0000000000003085","article-title":"Efficacy and safety of eliapixant in diabetic neuropathic pain and prediction of placebo responders with an exploratory novel algorithm: results from the randomized controlled phase 2a PUCCINI study","volume":"165","author":"Bouhassira","year":"2024","journal-title":"Pain"},{"key":"10.1016\/j.ejmech.2026.119150_bib106","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12905-024-03188-8","article-title":"Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study","volume":"24","author":"Parke","year":"2024","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.ejmech.2026.119150_bib107","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00408-023-00621-x","article-title":"Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study","volume":"201","author":"Dicpinigaitis","year":"2023","journal-title":"Lung"},{"key":"10.1016\/j.ejmech.2026.119150_bib108","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.bmcl.2017.04.060","article-title":"Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 1: initial structure-activity relationship studies of a hit from a high throughput screening","volume":"28","author":"Tobinaga","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib109","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bmcl.2019.01.039","article-title":"Pyrrolinone derivatives as a new class of P2X3 receptor antagonists part 2: discovery of orally bioavailable compounds","volume":"29","author":"Tobinaga","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127636","article-title":"Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 3: structure-activity relationships of pyrropyrazolone derivatives","volume":"30","author":"Tobinaga","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3003777","article-title":"Structure of the human P2X3 receptor reveals the basis for subtype-selective inhibition by sivopixant","volume":"24","author":"Zhao","year":"2026","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2026.119150_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127833","article-title":"Dioxotriazine derivatives as a new class of P2X3 receptor antagonists: identification of a lead and initial SAR studies","volume":"37","author":"Kai","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128384","article-title":"Discovery of clinical candidate Sivopixant (S-600918): lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists","volume":"52","author":"Kai","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","article-title":"A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"key":"10.1016\/j.ejmech.2026.119150_bib118","doi-asserted-by":"crossref","first-page":"14443","DOI":"10.1021\/acs.jmedchem.4c01214","article-title":"Discovery of triazolopyrimidine derivatives as selective P2X3 receptor antagonists binding to an unprecedented allosteric site as evidenced by cryo-electron microscopy","volume":"67","author":"Kim","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib115","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ejmech.2013.10.026","article-title":"Design and synthesis of potent and selective P2X3 receptor antagonists derived from PPADS as potential pain modulators","volume":"70","author":"Cho","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib116","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1021\/acschemneuro.6b00401","article-title":"Discovery of potent antiallodynic agents for neuropathic pain targeting P2X3 receptors","volume":"8","author":"Jung","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2026.119150_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27041337","article-title":"Synthesis and structure-activity relationship studies of benzimidazole-4,7-dione-Based P2X3 receptor antagonists as novel anti-nociceptive agents","volume":"27","author":"Bae","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119150_bib119","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2008.05.011","article-title":"Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X2\/3 receptor function and exerts an analgesic effect in pain models","volume":"589","author":"Kakimoto","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2220\/biomedres.34.137","article-title":"Analgesic effects of minodronate on formalin-induced acute inflammatory pain in rats","volume":"34","author":"Segawa","year":"2013","journal-title":"Biomed. Res."},{"key":"10.1016\/j.ejmech.2026.119150_bib121","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2220\/biomedres.39.261","article-title":"Analgesic effects of minodronate in a rat chronic pain model","volume":"39","author":"Kasukawa","year":"2018","journal-title":"Biomed. Res."},{"key":"10.1016\/j.ejmech.2026.119150_bib122","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13063-024-08364-7","article-title":"Efficacy and safety of minodronate in the treatment of postmenopausal osteoporosis with low back pain: a single-centre, randomized and open-label controlled trial","volume":"25","author":"Wang","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.ejmech.2026.119150_bib123","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.2147\/CIA.S541940","article-title":"Comparative effects of minodronate and alendronate on low back pain in postmenopausal osteoporosis and age influence: a head-to-head, randomized clinical trial","volume":"20","author":"Wang","year":"2025","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.ejmech.2026.119150_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115432","article-title":"Minodronate","volume":"137","author":"Matsumoto","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.ejmech.2026.119150_bib125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2147\/TCRM.S149236","article-title":"Minodronate for the treatment of osteoporosis","volume":"14","author":"Ohishi","year":"2018","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejmech.2026.119150_bib126","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1744-8069-5-20","article-title":"Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief","volume":"5","author":"Nagata","year":"2009","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ejmech.2026.119150_bib127","first-page":"94","article-title":"Paroxetine attenuates the development and existing pain in a rat model of neurophatic pain, Iran","volume":"18","author":"Zarei","year":"2014","journal-title":"Biomed. J."},{"key":"10.1016\/j.ejmech.2026.119150_bib128","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1085\/jgp.200910336","article-title":"P2X4 receptors in activated C8-B4 cells of cerebellar microglial origin","volume":"135","author":"Toulme","year":"2010","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.ejmech.2026.119150_bib129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165189","article-title":"Duloxetine inhibits microglial P2X4 receptor function and alleviates neuropathic pain after peripheral nerve injury","volume":"11","author":"Yamashita","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119150_bib130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000350119","article-title":"Investigation of the inhibitory effects of the benzodiazepine derivative, 5-BDBD on P2X4 purinergic receptors by two complementary methods","volume":"32","author":"Bal\u00e1zs","year":"2013","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2026.119150_bib131","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s10194-019-1070-4","article-title":"Microglia P2X4R-BDNF signalling contributes to central sensitization in a recurrent nitroglycerin-induced chronic migraine model","volume":"21","author":"Long","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejmech.2026.119150_bib132","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/molpharm.121.000402","article-title":"Structural basis of the negative allosteric modulation of 5-BDBD at human P2X4 receptors","volume":"101","author":"Bidula","year":"2022","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib133","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/1061186X.2024.2367563","article-title":"The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis","volume":"32","author":"Di Salvo","year":"2024","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejmech.2026.119150_bib134","doi-asserted-by":"crossref","first-page":"11194","DOI":"10.1021\/acs.jmedchem.9b01304","article-title":"Discovery and characterization of the potent and selective P2X4 inhibitor N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and structure-guided amelioration of its CYP3A4 induction profile","volume":"62","author":"Werner","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib135","doi-asserted-by":"crossref","first-page":"9576","DOI":"10.1021\/jm300845v","article-title":"N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists","volume":"55","author":"Hernandez-Olmos","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112261","article-title":"P2X4 receptor-dependent Ca2+ influx in model human monocytes and macrophages","volume":"18","author":"Layhadi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119150_bib137","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.bmc.2013.12.035","article-title":"Carbamazepine derivatives with P2X4 receptor-blocking activity","volume":"22","author":"Tian","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib138","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neuroscience.2018.12.003","article-title":"Diabetes-induced neuropathic mechanical hyperalgesia depends on P2X4 receptor activation in dorsal root ganglia","volume":"398","author":"Teixeira","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2026.119150_bib139","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11302-024-10005-2","article-title":"Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist","volume":"20","author":"Nagel","year":"2024","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2026.119150_bib140","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1021\/acsptsci.4c00688","article-title":"Species differences of P2X4 receptor modulators","volume":"8","author":"Nagel","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2026.119150_bib141","series-title":"Novel P2X4 Receptor Antagonist NC-2600 Attenuated Allodynia Induced by Sciatic Nerve Injury., 16th World Congress on Pain","author":"Imai","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119150_bib142","first-page":"73","article-title":"P2X4 receptor mediates macrophage infiltration leading to endometriotic cyst epithelium proliferation and hyperalgesia in mouse model","volume":"6","author":"Nagata","year":"2025","journal-title":"F S Sci"},{"key":"10.1016\/j.ejmech.2026.119150_bib143","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1021\/jm051202e","article-title":"Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists","volume":"49","author":"Nelson","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib144","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1016\/j.bmcl.2007.04.075","article-title":"Novel and potent 3-(2,3-dichlorophenyl)-4-(benzyl)-4H-1,2,4-triazole P2X7 antagonists","volume":"17","author":"Carroll","year":"2007","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/jnr.24645","article-title":"Suppression of active phase voluntary wheel running in male rats by unilateral chronic constriction injury: enduring therapeutic effects of a brief treatment of morphine combined with TLR4 or P2X7 antagonists","volume":"100","author":"Green-Fulgham","year":"2022","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejmech.2026.119150_bib146","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bbr.2009.05.018","article-title":"The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice","volume":"204","author":"Honore","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2026.119150_bib147","doi-asserted-by":"crossref","first-page":"eado5084","DOI":"10.1126\/sciadv.ado5084","article-title":"P2X7 receptors exhibit at least three modes of allosteric antagonism","volume":"10","author":"Oken","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.119150_bib148","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1021\/jm8015848","article-title":"Discovery and biological evaluation of novel cyanoguanidine P2X7 antagonists with analgesic activity in a rat model of neuropathic pain","volume":"52","author":"Perez-Medrano","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib149","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neuropharm.2008.06.012","article-title":"[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors","volume":"56","author":"Donnelly-Roberts","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2026.119150_bib150","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1021\/jm701516f","article-title":"Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists","volume":"51","author":"Nelson","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib151","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1016\/j.bmcl.2010.03.096","article-title":"Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor","volume":"20","author":"Chambers","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib152","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1016\/j.bmcl.2010.05.107","article-title":"Structure-activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor","volume":"20","author":"Beswick","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib153","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1016\/j.bmcl.2010.07.033","article-title":"Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor","volume":"20","author":"Abdi","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib154","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.2012.04320.x","article-title":"Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects","volume":"75","author":"Ali","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib155","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1016\/j.bmcl.2010.09.101","article-title":"Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X7 receptor","volume":"20","author":"Abberley","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib156","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1124\/jpet.108.141853","article-title":"Characterization of N-(adamantan-1-ylmethyl)-5-[(3R-amino-pyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 antagonist in animal models of pain and inflammation","volume":"327","author":"Broom","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119150_bib157","first-page":"878","article-title":"Targeting the P2X7 receptor in rheumatoid arthritis: biological rationale for P2X7 antagonism","volume":"32","author":"McInnes","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.119150_bib158","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/annrheumdis-2011-143578","article-title":"Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine","volume":"71","author":"Keystone","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2026.119150_bib159","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3892\/ijmm.2016.2770","article-title":"Blocking of the P2X7 receptor inhibits the activation of the MMP-13 and NF-\u03baB pathways in the cartilage tissue of rats with osteoarthritis","volume":"38","author":"Hu","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119150_bib160","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1016\/j.bmcl.2011.04.034","article-title":"Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 1","volume":"21","author":"Matasi","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib161","doi-asserted-by":"crossref","first-page":"7287","DOI":"10.1016\/j.bmcl.2011.10.037","article-title":"Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: part 2","volume":"21","author":"Brumfield","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib162","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.bmcl.2011.04.077","article-title":"Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535","volume":"21","author":"Duplantier","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119150_bib163","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3899\/jrheum.110874","article-title":"Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate","volume":"39","author":"Stock","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejmech.2026.119150_bib164","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0022-3565(24)38838-X","article-title":"Complexities of measuring antagonist potency at P2X(7) receptor orthologs","volume":"296","author":"Hibell","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119150_bib165","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1074\/jbc.M010353200","article-title":"A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor","volume":"276","author":"Gu","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib166","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-65847-0","article-title":"Understanding interspecies drug response variations between human and rodent P2X7 receptors","volume":"16","author":"Guo","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119150_bib167","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262110265","article-title":"Genetic variations in the P2X7 receptor: opportunities and challenges for drug development","volume":"26","author":"Cheah","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119150_bib168","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1021\/ml400040v","article-title":"Synthesis and pharmacological characterization of two novel, brain penetrating P2X7 antagonists","volume":"4","author":"Letavic","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119150_bib169","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/bph.12314","article-title":"Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567","volume":"170","author":"Bhattacharya","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/jpet.114.218487","article-title":"Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432","volume":"351","author":"Lord","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119150_bib171","doi-asserted-by":"crossref","first-page":"8535","DOI":"10.1021\/acs.jmedchem.6b00989","article-title":"Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a small molecule antagonist of the P2X7 receptor","volume":"59","author":"Swanson","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib172","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/acs.jmedchem.7b00408","article-title":"4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-based P2X7 receptor antagonists: optimization of pharmacokinetic properties leading to the identification of a clinical candidate","volume":"60","author":"Letavic","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib173","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1177\/0269881120914206","article-title":"Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial","volume":"34","author":"Recourt","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib174","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1124\/mol.54.1.22","article-title":"Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues","volume":"54","author":"Humphreys","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119150_bib175","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/jm500324g","article-title":"Discovery of novel 2,5-dioxoimidazolidine-based P2X7 receptor antagonists as constrained analogues of KN62","volume":"58","author":"Park","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119150_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2025.105380","article-title":"AK1780, a selective P2X7 receptor antagonist with high central nervous system penetration, exhibits analgesic effect in rat neuropathic pain model","volume":"31","author":"Shinotsuka","year":"2025","journal-title":"J. Pain"},{"key":"10.1016\/j.ejmech.2026.119150_bib177","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.92829","article-title":"Structural insights into the orthosteric inhibition of P2X receptors by non-ATP analog antagonists","volume":"12","author":"Sheng","year":"2024","journal-title":"eLife"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426005957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:08:13Z","timestamp":1787040493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426005957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":177,"alternative-id":["S0223523426005957"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119150","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting P2X receptors for analgesia: Small molecule antagonists in development","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119150"}}